AI assistant
RIGEL PHARMACEUTICALS INC — Director's Dealing 2024
Feb 7, 2024
32801_dirs_2024-02-06_f3213442-1cc0-49fa-8a14-b46b508f0a13.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: RIGEL PHARMACEUTICALS INC (RIGL)
CIK: 0001034842
Period of Report: 2024-02-02
Reporting Person: Schorno Dean L (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-02-02 | Common Stock | S | 5601 | $1.1296 | Disposed | 409918 | Direct |
| 2024-02-05 | Common Stock | S | 7027 | $1.14 | Disposed | 402891 | Direct |
Footnotes
F1: These shares were sold to cover tax withholding due upon vesting of Restricted Stock Units. Such "sales to cover" were automatically effected to satisfy tax withholding obligations and do not represent a discretionary trade by the Reporting Person.
F2: The price reported in Column 4 is the weighted average price. These shares were sold in multiple transactions ranging from $1.1228 to $1.13. Upon request, the Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission staff, full information regarding the shares sold at each such separate price.